Pai, Helen
Ndjeka, Norbert
Mbuagbaw, Lawrence
Kaniga, Koné
Birmingham, Eileen
Mao, Gary
Alquier, Lori
Davis, Kourtney
Bodard, Arianne
Williams, Abeda
Van Tongel, Magalie
Thoret-Bauchet, Florence
Omar, Shaheed V.
Bakare, Nyasha
Funding for this research was provided by:
Janssen Research & Development
Article History
Received: 3 March 2022
Accepted: 9 November 2022
First Online: 21 November 2022
Declarations
:
: The study was approved by the Research Ethics Committee of the Human Sciences Research Council, which is registered with the South African National Health Research Ethics Council (REC-290808-015). Informed consent from patients was not required, as each patient’s consent to treatment was collected in EDRWeb system as part of the existing national TB program.
: Not applicable.
: HP, KK, NB, EB, GM, LA, KD, AB, AW, MVT and FT-B are employees of Janssen Pharmaceuticals, participating in the development of bedaquiline, and all are potential stockholders of Johnson & Johnson. NN has no relevant disclosures relating to this study. He serves under the National Department of Health, South Africa. LM received consultancy fees from Janssen for the design and analysis of this study. SVO has no competing interests to declare.